Perspectives
Biosimilar Pipeline Quarterly Update: June 2023
Critical updates in an ever-changing environment
June 22, 2023This quarterly pipeline wrap-up provides a review of newly approved biosimilars, an update on the biosimilar pipeline and news of note on biosimilars in the approval process. See separate articles for updates on traditional drugs, specialty drugs and cell/gene therapies.
New Drug Information
- None
New Indications
- None
Biosimilar Product Approvals in the Past Twelve Months
| Generic Name | Brand Name | Reference
Product |
Manufacturer | Indication(s) | Route of Administration | Month Approved |
| adalimumab-aaty | Yuflyma® | Humira® | Celltrion | Autoimmune | SC | May 2023 |
| adalimumab-aacf | Idacio® | Humira® | Fresenius | Autoimmune | SC | December 2022 |
| insulin glargine-aglr
Interchangeable biosimilar |
Rezvoglar® | Lantus® | Eli Lilly | Diabetes | SC | November 2022 |
| bevacizumab-adcd | Vegzelma® | Avastin® | Celltrion | Oncology | IV | September 2022 |
| pegfilgrastim-fpgk | Stimufend® | Neulasta® | Fresenius Kabi | Neutropenia | IV or SC | September 2022 |
| adalimumab-bwwd 100mg/mL | Hadlima® HC | Humira® | Samsung Bioepis/ Organon | Autoimmune | SC | August 2022 |
| ranibizumab-eqrn
Interchangeable biosimilar |
Cimerli® | Lucentis® | Coheres biosciences/bioeq | Age-related macular degeneration | Injection into the eye | August 2022 |
Biosimilar Pipeline
| Generic Name | Brand Name | Manufacturer | Indication(s) | Route of Administration | Anticipated Approval date* |
| Oncology | |||||
| SB8 (bevacizumab biosimilar) | N/A (Avastin® biosimilar) | Samsung Bioepis/ Merck | Oncology | IV | 2023 |
| FKB238 (bevacizumab biosimilar) | N/A (Avastin® biosimilar) | Centus Biotherapeutics | Oncology | IV | 2023 |
| BAT-1706 (bevacizumab biosimilar) | N/A (Avastin® biosimilar) | Bio-thera solutions | Oncology | IV | 2023 |
| MYL1402O (bevacizumab biosimilar) | Abevmy® (Avastin® biosimilar) | Mylan/Biocon | Oncology | IV | 2023 |
| HLX02 (trastuzumab biosimilar) | Zercepac® (Herceptin® biosimilar) | AccordBioPharma (Intas)/ Shanghai Henlius Biotech | Oncology | IV | 2023 |
| Blood Modifiers | |||||
| pegfilgrastim | Lupifil-p® (Neulasta® biosimilar) | Lupin | Neutropenia | SC | 2023 |
| pegfilgrastim | Lapelga® (Neulasta® biosimilar) | Apotex/Accord | Neutropenia | SC | 2023 |
| pegfilgrastim | Udenyca® OBI (Neulasta biosimilar) | Coherus BioSciences | Neutropenia | On body device | 2023 |
| filgrastim | Grastofil® (Neupogen® biosimilar) | Apotex/Accord | Neutropenia | SC | 2023 |
| Ophthalmology | |||||
| MYL1701P (aflibercept) | N/A (Eylea® biosimilar) | Mylan | Age-related macular degeneration | Injection into the eye | 2023 |
| Autoimmune | |||||
| MSB11456 (tocilizumab) | N/A (Actemra® IV/SC biosimilar) | Fresenius | Autoimmune | IV/SC | 2Q2023 |
| BIIB800 (tocilizumab) | N/A (Actemra® IV/SC biosimilar) | Biogen | Autoimmune | IV/SC | 10/2023 |
| AVT02 (adalimumab) | N/A (Humira® SC biosimilar) | Alvotech | Autoimmune | SC | 2023 |
| ABP654
(ustekinumab) |
N/A (Stelara® SC biosimilar) | Amgen | Autoimmune | SC | 2H2023 |
| AVT04
(ustekinumab) |
N/A (Stelara® SC biosimilar) | Alvogen/Alvotech | Autoimmune | SC | 2H2023 |
| Immunosuppressant | |||||
| PB006 (natalizumab) | Tyruko® (Tysabri® biosimilar) | Sandoz-Polpharma | Multiple sclerosis | IV | 2023 |
| Bone Health | |||||
| GP2411 (denosumab) | N/A (Prolia® biosimilar) | Sandoz | Osteoporosis | SC | 12/2023 |
Related news
Perspectives
September 25, 2023
Specialty Drug Pipeline Quarterly Update: September 2023
This monthly pipeline wrap-up provides a review of newly approved specialty drugs, recent…
Perspectives
September 25, 2023
Traditional Drug Pipeline Quarterly Update: September 2023
This monthly pipeline wrap-up provides a review of newly approved traditional drugs, recent…
Perspectives
September 25, 2023
Gene/Cell Therapy Quarterly Update: September 2023
This quarterly pipeline wrap-up provides a review of newly approved gene and cell…